We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Novel Coronavirus Breathalyzer Test Detects COVID-19 Non-Invasively in Seconds

By LabMedica International staff writers
Posted on 26 Aug 2020
A novel breathalyzer uses intelligent nanotechnology that is capable of rapidly detecting COVID-19 in exhaled breath and has “the potential to serve as a monitoring and epidemic control tool.”

A team of scientists from Technion - Israel Institute of Technology (Haifa, Israel) and Russell Berrie Nanotechnology Institute (Haifa, Israel), in collaboration with Chinese researchers, has devised a novel breath analyzer test to rapidly detect the disease caused by the novel coronavirus. More...
The testing device is an intelligent nanotechnology that can rapidly detect COVID-19 from specific volatile organic compounds (VOCs) in exhaled breath.

The efficacy of the COVID-19 breath analyzer testing device, which is comprised of a nanomaterial-based sensor array, was successfully validated in March by a preliminary case-control clinical study in China. It can detect disease-specific biomarkers in exhaled breath with 92% accuracy, 100% sensitivity, and 84% specificity. While a larger cohort study is still needed to validate the results, the researchers envision the test’s utility as a screening tool for airports, shopping centers, and other public places where the risk of community spread is high.

The pre-screening diagnostic system could offer a screening solution that can be performed at home or point-of-care facilities, greatly reducing unneeded confirmatory tests and reducing the burden on hospitals. Importantly, the artificial intelligence of the device can be modified and applied to any other infectious diseases. The researchers believe that this approach can serve as a platform for a rapidly available diagnostic tool that can be used in the case of a new disease outbreak.

Related Links:
Technion – Israel Institute of Technology
Russell Berrie Nanotechnology Institute



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.